Related references
Note: Only part of the references are listed.Recent Progress in the Diagnosis and Treatment of Ovarian Cancer
Danijela Jelovac et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?
T. Le et al.
GYNECOLOGIC ONCOLOGY (2011)
Clinical predictors of bevacizumab-associated gastrointestinal perforation
Janos L. Tanyi et al.
GYNECOLOGIC ONCOLOGY (2011)
Effect of Screening on Ovarian Cancer Mortality The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial
Saundra S. Buys et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
Antonella Sistigu et al.
SEMINARS IN IMMUNOPATHOLOGY (2011)
Gynaecological Malignancies from Palliative Care Perspective
Kamlesh Mishra
INDIAN JOURNAL OF PALLIATIVE CARE (2011)
VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment
Steven G. Patten et al.
BMC CANCER (2010)
End of life care for women with gynecologic cancers
L. Barbera et al.
GYNECOLOGIC ONCOLOGY (2010)
A review of issues surrounding quality of life among women with ovarian cancer
Lucybeth Nieves Arriba et al.
GYNECOLOGIC ONCOLOGY (2010)
Hospice enrollment for terminally ill patients with gynecologic malignancies: Impact on outcomes and interventions
Erin A. Keyser et al.
GYNECOLOGIC ONCOLOGY (2010)
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study
Jean A. Hurteau et al.
GYNECOLOGIC ONCOLOGY (2010)
Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer
Yoh Watanabe et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2010)
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy
Tristan D. Yan et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2010)
Intraperitoneal Drug Therapy: An Advantage
Kunal Chaudhary et al.
CURRENT CLINICAL PHARMACOLOGY (2010)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Palliative Care
Michael H. Levy et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2009)
A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma
Levi S. Downs et al.
CANCER (2008)
Thalidomide-induced reversible interstitial pneumonitis in a patient with recurrent ovarian cancer
Barbara M. Buttin et al.
GYNECOLOGIC ONCOLOGY (2008)
Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer
Chad A. Hamilton et al.
GYNECOLOGIC ONCOLOGY (2008)
The role of chemotherapy at the end of life: When is enough, enough?
Sarah Elizabeth Harrington et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: A gynecologic oncology group study
Laura J. Havrilesky et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A phase 1 study of MORAb-009, a monoclonal antibody against mesothelin in pancreatic cancer, mesothelioma and ovarian adenocarcinoma
D. K. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: A Gynecologic Oncology Group study
Lari B. Wenzel et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer
Mary E. Gordinier et al.
JOURNAL OF PALLIATIVE MEDICINE (2007)
Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma
John K. Chan et al.
GYNECOLOGIC ONCOLOGY (2006)
Gynecologic oncology patients' satisfaction and symptom severity during palliative chemotherapy
Vivian E. von Gruenigen et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2006)
The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma
T. Michael Numnum et al.
GYNECOLOGIC ONCOLOGY (2006)
Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis
Nadeem Ikhlaque et al.
AMERICAN JOURNAL OF HEMATOLOGY (2006)
Palliation of malignant ascites
SM Rosenberg
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2006)
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
DK Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Resource utilization for ovarian cancer patients at the end of life: How much is too much?
SN Lewin et al.
GYNECOLOGIC ONCOLOGY (2005)
Identifying patients unlikely to benefit from further chemotherapy: A descriptive study of outcome at each relapse in ovarian cancer
PJ Hoskins et al.
GYNECOLOGIC ONCOLOGY (2005)
Futility: Clinical decisions at the end-of-life in women with ovarian cancer
VE von Gruenigen et al.
GYNECOLOGIC ONCOLOGY (2005)
Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin
S Mabuchi et al.
ENDOCRINOLOGY (2004)
Attitudes to chemotherapy in patients with ovarian cancer
RT Penson et al.
GYNECOLOGIC ONCOLOGY (2004)
Frequency of symptoms of ovarian cancer in women presenting to primary care clinics
BA Goff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Topotecan dosing guidelines in ovarian cancer: Reduction and management of hematologic toxicity
DK Armstrong
ONCOLOGIST (2004)
Intraperitoneal antineoplastic drug delivery: rationale and results
M Markman
LANCET ONCOLOGY (2003)
Adjuvant treatment for early ovarian cancer: A randomized phase III trial of intraperitoneal P-32 or intravenous cyclophosphamide and cisplatin - A gynecologic oncology group study
RC Young et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Treatment preferences in recurrent ovarian cancer
KA Donovan et al.
GYNECOLOGIC ONCOLOGY (2002)
Secondary and tertiary palliative care in US hospitals
CF von Gunten
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Metronomic scheduling: the future of chemotherapy?
G Gasparini
LANCET ONCOLOGY (2001)
Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
AN Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Current concepts: Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract.
TH Baron
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer
C Doyle et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer
AN Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group study
WP McGuire et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
